Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growthJaya Sangodkar, Goutham Narla, Abbey Perl et al.|Journal of Clinical Investigation|2017Cited by 200
Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).Marwan Fakih, Andrew Scott Paulson, Shruthi Ravimohan et al.|Journal of Clinical Oncology|2021Cited by 74
Abstract A38: Therapeutic targeting of oncogenic KRAS signaling using a novel small molecule agonist of the PP2A tumor suppressor geneJaya Sangodkar, Goutham Narla, Sahar Mazhar et al.|Molecular Cancer Research|2014Cited by 0
Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancerJaya Sangodkar, Goutham Narla, Rita Tohmé et al.|Cancer Research|2016Cited by 0
Abstract 5329: Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancerJaya Sangodkar, Goutham Narla, Sudeh Izadmehr et al.|Cancer Research|2015Cited by 0